Multiple Myeloma Clinical Trial
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
Summary
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus.
The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.
Eligibility Criteria
Inclusion Criteria:
Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma.
Access to a computer or electronic device with internet access, or phone
Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma
Willing to give electronically-signed consent
Ability to read questions in English
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.